Advertisement
News
Advertisement

Avinger To Reveal CONNECT II Clinical Trial Results for First-Ever Imaging CTO Catheter To Help Save PAD Patients’ Legs

Tue, 10/02/2012 - 1:29pm
The Associated Press

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Oct 2, 2012--Avinger, Inc., a medical device manufacturer of innovative, multi-functional catheters for treating patients with Peripheral Artery Disease (PAD), announces it will reveal its CONNECT II global clinical trial results at the Vascular Interventional Advances (VIVA) Conference 2012 in Las Vegas, Nevada, October 9-12, 2012.

CONNECT II is a global clinical study that evaluated the safety and efficacy of Ocelot, the first-ever interventional Chronic Total Occlusion (CTO) crossing catheter to incorporate Optical Coherence Tomography, or OCT. This technology is used to image inside the artery, allowing physicians to navigate, see, and cross totally blocked arteries in the legs of patients suffering from PAD.

PAD is a silent, unsung pandemic that affects approximately 18 million adults in the U.S., 30 million globally and is the leading cause of amputation in patients over 50. According to the American Heart Association journal Circulation, it afflicts even more women than men.

Final results will be revealed by Interventional Cardiologist Dr. Matt Selmon, CONNECT II Co-Principal Investigator of Heart Hospital of Austin. The venue will be the Late Breaking Clinical Trial session in the Wynn Hotel on Thursday, October 11, 2012 at 1:50 p.m. PT. Avinger representatives will also be at VIVA Booth #320 throughout the week.

To learn more about PAD, visit http://avinger.com/patients.

About Avinger Founded in 2007 by renowned cardiologist and medical device entrepreneur Dr. John B. Simpson, Avinger develops next-generation catheter-based technologies for the treatment of peripheral artery disease (PAD). Leveraging core competencies in medical device catheter engineering and intravascular Optical Coherence Tomography (OCT), Avinger markets Wildcat and Kittycat catheters, and received CE Mark in 2011 to market  Ocelot, the first ever real-time OCT crossing catheter.  www.avinger.com.

CONTACT: Avinger PR Deborah Getz, +1 650-241-7900 dgetz@avinger.com or Press Inquiries: Mortar PR Allyson Stinchfield, +1 415-772-9907 x120 allyson@mortaragency.com KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA NEVADA INDUSTRY KEYWORD: HEALTH CARDIOLOGY CLINICAL TRIALS MEDICAL DEVICES RADIOLOGY RESEARCH SCIENCE SOURCE: Avinger, Inc. Copyright Business Wire 2012 PUB: 10/02/2012 01:29 PM/DISC: 10/02/2012 01:29 PM http://www.businesswire.com/news/home/20121002006641/

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading